© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Melatonin and Breast Cancer: A Prospective Study
Affiliations of authors: Cancer Research UK, Epidemiology Unit, University of Oxford, Oxford, U.K. (RCT, TJK); Academic Oncology Unit, Thomas Guy House, Guy’s Hospital, London, U.K. (DSA, ISF)
Correspondence to: Ruth C. Travis, MSc, Cancer Research UK, Epidemiology Unit, University of Oxford, Oxford OX2 6HE, U.K. (e-mail: ruth.travis{at}cancer.org.uk)
Background: Experimental data from animals suggest a protective role for the pineal hormone melatonin in the etiology of breast cancer, but results from the few retrospective case–control studies that examined the association in humans have been inconsistent. To determine whether low levels of endogenous melatonin are associated with an increased risk for developing breast cancer, we conducted a prospective nested case–control study among British women. Methods: Concentrations of 6-sulfatoxymelatonin, the main metabolite of melatonin in urine and a validated marker of circulating melatonin levels, were measured by radioimmunoassay in 24-hour urine samples collected from women shortly after enrollment in the prospective Guernsey III Study. Levels of 6-sulfatoxymelatonin were compared among 127 patients diagnosed with breast cancer during follow-up and among 353 control subjects, matched for age, recruitment date, menopausal status, and day of menstrual cycle for premenopausal women or number of years postmenopausal for postmenopausal women. Associations were examined by analyses of covariance and conditional logistic regression. All tests of statistical significance were two-sided. Results: No statistically significant differences in urinary 6-sulfatoxymelatonin concentrations were observed between women who developed breast cancer and control subjects among premenopausal or postmenopausal women (P= .8 and P= .9, respectively). When data from premenopausal and postmenopausal women were combined in a multivariable analysis adjusted for potential confounders and grouped into three categories defined by 6-sulfatoxymelatonin tertiles of control subjects, the level of 6-sulfatoxymelatonin excreted was not statistically significantly associated with the risk of breast cancer (odds ratio [OR] for breast cancer = 0.95, 95% confidence interval [CI] = 0.55 to 1.65, comparing the middle category with the lowest category of 6-sulfatoxymelatonin concentration, and OR = 0.99, 95% CI = 0.58 to 1.70, comparing the highest category with the lowest category). Conclusion: We found no evidence that the level of melatonin is strongly associated with the risk for breast cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: Melatonin and Breast Cancer: A Prospective Study
- William J. M. Hrushesky and David E. Blask
J Natl Cancer Inst 2004 96: 888-889.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  E. S. Schernhammer, F. Berrino, V. Krogh, G. Secreto, A. Micheli, E. Venturelli, S. Sieri, C. T. Sempos, A. Cavalleri, H. J. Schunemann, et al. Urinary 6-Sulfatoxymelatonin Levels and Risk of Breast Cancer in Postmenopausal Women J Natl Cancer Inst, June 18, 2008; 100(12): 898 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Wu, R. Wang, W.-P. Koh, F. Z. Stanczyk, H.-P. Lee, and M. C. Yu Sleep duration, melatonin and breast cancer among Chinese women in Singapore Carcinogenesis, June 1, 2008; 29(6): 1244 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Nagata, T. Matsubara, T. Hara, H. Fujita, Y. Nagao, S. Yamamoto, C. Shibuya, Y. Kashiki, and H. Shimizu Urinary 6-Sulfatoxymelatonin and Mammographic Density in Japanese Women Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2509 - 2512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. O'Leary, E. R. Schoenfeld, R. G. Stevens, G. C. Kabat, K. Henderson, R. Grimson, M. D. Gammon, M. C. Leske, and for the Electromagnetic Fields and Breast Cancer o Shift Work, Light at Night, and Breast Cancer on Long Island, New York Am. J. Epidemiol., August 15, 2006; 164(4): 358 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Knight, S. Thompson, J. M. Raboud, and B. R. Hoffman Light and Exercise and Melatonin Production in Women Am. J. Epidemiol., December 1, 2005; 162(11): 1114 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Verkasalo, K. Lillberg, R. G. Stevens, C. Hublin, M. Partinen, M. Koskenvuo, and J. Kaprio Sleep Duration and Breast Cancer: A Prospective Cohort Study Cancer Res., October 15, 2005; 65(20): 9595 - 9600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. M. Forssen, L. E. Rutqvist, A. Ahlbom, and M. Feychting THE AUTHORS REPLY Am. J. Epidemiol., August 15, 2005; 162(4): 393 - 394. [Full Text] [PDF]
|
|
|
|
|
|
E. S. Schernhammer and S. E. Hankinson Urinary Melatonin Levels and Breast Cancer Risk J Natl Cancer Inst, July 20, 2005; 97(14): 1084 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kayumov, R. F. Casper, R. J. Hawa, B. Perelman, S. A. Chung, S. Sokalsky, and C. M. Shapiro Blocking Low-Wavelength Light Prevents Nocturnal Melatonin Suppression with No Adverse Effect on Performance during Simulated Shift Work J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2755 - 2761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. M. Hrushesky and D. E. Blask Re: Melatonin and Breast Cancer: A Prospective Study J Natl Cancer Inst, June 2, 2004; 96(11): 888 - 889. [Full Text] [PDF]
|
|